Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Protagonist Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was MXN12,577 Mil.
Warning Sign:
If a company builds assets at 63.1% a year, faster than its revenue growth rate of 23% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Protagonist Therapeutics's average Total Assets Growth Rate was -10.80% per year.
During the past 3 years, the average Total Assets Growth Rate was 112.10% per year.
During the past 5 years, the average Total Assets Growth Rate was 63.10% per year.
During the past 10 years, the average Total Assets Growth Rate was 30.20% per year.
During the past 12 years, Protagonist Therapeutics's highest 3-Year average Total Assets Growth Rate was 169.90%. The lowest was -21.60%. And the median was 25.10%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Protagonist Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Protagonist Therapeutics Total Assets Related Terms
Protagonist Therapeutics Total Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Protagonist Therapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protagonist Therapeutics (MEX:PTGX) has a Total Assets of MXN12,577 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Protagonist Therapeutics and its competitors.
Is Protagonist Therapeutics' Total Assets too high?
Protagonist Therapeutics' current Total Assets is MXN12,577 Mil. Overall, Protagonist Therapeutics has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Protagonist Therapeutics' Total Assets compare to IMVT and SYRE?
Protagonist Therapeutics' Total Assets of MXN12,577 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Protagonist Therapeutics and its competitors. Protagonist Therapeutics's current Total Assets is MXN12,577 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagonist Therapeutics stock overvalued right now?
Protagonist Therapeutics (MEX:PTGX) has a current Total Assets of MXN12,577 Mil. The stock's GF Value™ is MXN775.62, compared to a current price of MXN1,565.33 — trading 101.8% above its estimated fair value. The current Total Assets is MXN12,577 Mil. Protagonist Therapeutics' overall GF Score™ is 47/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Protagonist Therapeutics (MEX:PTGX), the current Total Assets is MXN12,577 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Protagonist Therapeutics (MEX:PTGX) Overvalued in 2026?
Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued.
The current stock price of MXN1,565.33 is trading 101.8% above its estimated GF Value™ of MXN775.62.
Key valuation signals for MEX:PTGX:
Total Assets: MXN12,577 Mil
GF Value™: MXN775.62 vs. price of MXN1,565.33 (101.8% above fair value)
No single metric tells the full story. See the MEX:PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
47GF Score
Get the complete analysis for MEX:PTGX
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PTGX has been successfully added to your 
